Granules India Limited has recalled approximately 23.1 million Ranitidine Tablets (USP 150mg), a generic medication used to treat heartburn and stomach ulcers. The recall was initiated because testing revealed the presence of N-nitrosodimethylamine (NDMA), an impurity classified as a probable human carcinogen. These prescription-strength tablets were distributed in large 10,000-count bags to distributors in Oregon, New York, and New Jersey. Consumers taking this medication should contact their doctor or pharmacist to discuss alternative treatments, as stopping the medication without a replacement could pose health risks.
The product contains NDMA, an environmental contaminant that is classified as a probable human carcinogen. While NDMA can be found in water and foods, exposure to elevated levels over a long period may increase the risk of developing cancer.
Pharmacy refund and healthcare consultation.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.